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Promoter DNA hypermethylation is an important biomarker of hepatocellular carcinoma
(HCC), supporting the potential utility of demethylating agents in this disease.
Guadecitabine (SGI-110) is a second-generation hypomethylating agent formulated as a
dinucleotide of decitabine and deoxyguanosine that yields longer half-life and more
extended decitabine exposure than decitabine IV infusion. Here we performed preclinical
evaluation of SGI-110 in HCC models to guide the design of a phase I/II clinical trial. HCC
cell lines and xenograft models were used to determine the antitumor activity of SGI-110
as a single agent and in combination with oxaliplatin. Pretreatment with low doses of
SGI-110 significantly synergized with oxaliplatin yielding enhanced cytotoxicity. The com-
bination of SGI-110 and oxaliplatin was well tolerated and significantly delayed tumor
growth in mice compared to oxaliplatin alone. Bromouridine-labeled RNA sequencing
(Bru-seq) was employed to elucidate the effects of SGI-110 and/or oxaliplatin on genome-
wide transcription. SGI-110 and the combination treatment inhibited the expression of
genes involved in WNT/EGF/IGF signaling. DNMT1 and survivin were identified as novel
PD markers to monitor the efficacy of the combination treatment. In conclusion, SGI-110
priming sensitizes HCC cells to oxaliplatin by inhibiting distinct signaling pathways. We
expect that this combination treatment will show low toxicity and high efficacy in patients.
Our study supports the use of the combination of low doses of SGI-110 and oxaliplatin in
HCC patients.
ª 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.oma; HMA, hypomethylating agent; Bru-seq, bromouridine-labeled RNA sequencing; GSEA,
cinal Chemistry, College of Pharmacy, Translational Oncology Program, University of Mich-
Plymouth Road, Bldg. 520, Room 1363, Ann Arbor, MI 48109-2800, USA. Tel.: þ1 734 647 2732.
Neamati).
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MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 7 9 9e1 8 1 418001. Introduction et al., 2014). Such desirable features make SGI-110 a clinicallyLiver cancer claimed 746,000 lives worldwide in 2012 (Ferlay J,
2013). With poor survival statistics and a growing rate of inci-
dence due to an increase in HCV infections and other liver dis-
eases in the population, liver cancer has now become the fifth
leading cause of cancer-related deaths in the United States
(Siegel et al., 2014). Eighty percent of all liver cancer cases
are hepatocellular carcinoma (HCC). Patients diagnosed at
advanced stage of the disease are not eligible for potential
curative treatment or transarterial chemoembolization, leav-
ing systemic treatment as the major remaining therapeutic
option. Sorafenib, a VEGFR, PDGFR and Raf kinase inhibitor,
is the only FDA approved drug since 2007 for use as palliative
treatment for these patients (Forner et al., 2012). Treatment
with sorafenib has been shown to improve median survival
and time to progression by 3 months in HCC patients
compared to placebo (Llovet et al., 2008). Unfortunately, drug
resistance and adverse events have limited its applicability
in the clinic. New effective treatments for HCC are in urgent
need.
Overexpression of DNA methyltransferases DNMT1 and
DNMT3A is a characteristic of HCC (Figure S1) (Wurmbach
et al., 2007; Fan et al., 2009; Roessler et al., 2010). Knocking
down DNMT1 significantly inhibits HCC cell proliferation
(Fan et al., 2009), further implicating an oncogenic role of
DNMT1. In line with overexpression of DNMTs, DNA hyper-
methylation in the promoter regions of tumor suppressor
genes like CDKN2A (p16) and CDH1 (E-cadherin) has been asso-
ciated with HCC. A series of DNA methylation-regulated bio-
markers specific for HCC have been identified by microarray
analyses and next generation sequencing (Nishida et al.,
2012; Shitani et al., 2012). Treatment with decitabine restores
transcription of many tumor suppressor genes silenced by
promoter hypermethylation and inhibits cell proliferation
(Suh et al., 2000; Neumann et al., 2012; Zhang et al., 2012).
Taken together, these results provide the impetus for the ther-
apeutic targeting of DNMTs in HCC.
Guadecitabine (SGI-110) is a dinucleotide comprising of
deoxyguanosine and the DNA demethylating agent decitabine
(2-deoxy-5’-aza-cytidine), an FDA approved agent for myelo-
displastic syndrome (MDS). When activated, decitabine is
incorporated into DNA and the presence of nitrogen at the 5
position of the pyrimidine leads to formation of covalent
DNA-protein adducts with DNMTs (Jones and Taylor, 1980;
Song et al., 2012). DNMT proteins bound to decitabine are
degraded, resulting in a down-regulation of total DNMT pro-
tein levels and the reduction in the hypermethylation pheno-
type. Unfortunately, decitabine is rather chemically unstable
in vivo. Catalyzed by cytidine deaminase (CDA), 2-deoxy-5’-
aza-cytidine is rapidly converted into the inactive metabolite
2-deoxy-5’-aza-uridine. Importantly, SGI-110 is a dinucleotide
of deoxyguanosine and decitabine to protect the latter from
CDA inactivation. SGI-110 is formulated as a pharmaceutically
stable subcutaneous injection formulation that yields longer
half-life and more extended decitabine exposure than decita-
bine IV infusion (Yoo et al., 2007; Chuang et al., 2010; Tellezappealing demethylating drug.
Combination treatments have advantages over single
agent applications in that they attack multiple targets making
it less likely for the tumor to develop resistance, and allow
anti-cancer agents to be used at lower doses reducing adverse
events. Oxaliplatin has been evaluated in combination with
gemcitabine (GEMOX) (Louafi et al., 2007) or with leucovorin
and fluorouracil (FOLFOX4) (Qin et al., 2013) in HCC. Although
no significant survival benefit was observed in the FOLFOX4
phase III trial, the efficacy reported in the GEMOX phase II trial
and the favorable safety profile shared by both studies suggest
the potential of oxaliplatin-based treatments for HCC pa-
tients. The combination of SGI-110 and cisplatin (Fang et al.,
2014) and carboplatin (Wang et al., 2014) showed encouraging
anti-tumor activity in ovarian cancer, implying potential ther-
apeutic utility of such combinations. However, the combina-
tion of SGI-110 and oxaliplatin has never been tested in HCC.
In this study we evaluated the in vivo efficacy of SGI-110 as a
single agent and in combination with oxaliplatin at low doses
as a novel therapy for HCC. Using Bru-seq, a recently devel-
oped next generation sequencing technique measuring the
newly synthesized RNA (Paulsen et al., 2013, 2014), we eluci-
dated the effects these agents have on the transcriptome in
HCC either alone or in combination. We discovered the
WNT/EGF/IGF signaling pathways as potential targets of the
combination treatment and identified DNMT1 and survivin
as novel PD markers. The findings from this study will be
used to guide the design of clinical studies of the use of SGI-
110 in combination with oxaliplatin for the treatment of HCC.2. Materials and methods
2.1. Cell culture
SNU-398, SNU-449, SNU-387, SNU-475, Hep-3B, Hep-G2 hepa-
tocellular carcinoma cell lines were obtained from ATCC
(Manassas, VA) in June 2012. Isoenzymology and STR analyses
were performed by ATCC to confirm species and cell line iden-
tity. No further authentication was performed in-house. Cells
were expanded into 10 tubes (1  106/tube) and frozen imme-
diately. All cell lines were cultured as monolayers and main-
tained in RPMI1640 supplemented with 10% fetal bovine
serum (FBS) in a humidified atmosphere with 5% CO2 at
37 C. Cells were kept in culture for 20 passages and discarded,
then a new batch of cells was used in subsequent experi-
ments. PlasmoTest (InvivoGen, San Diego, CA) were per-
formed every three weeks to confirm all cell lines were
mycoplasma-free.
2.2. Compound preparation
For in vitro experiments, 10 mM stock solution was prepared
by dissolving SGI-110 (Astex Pharmaceuticals, Dublin, CA) in
PBS. Solution was kept at 80 C for storage. For in vivo exper-
iments, SGI-110 was diluted in reconstitution solvent (65%
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stored at 4 C. Oxaliplatin was purchased from BIOTANG Inc.
(Lexington, MA) and freshly dissolved in DMSO to prepare a
10 mM stock solution. Z-VAD-fmk (Tocris, Minneapolis, MN)
and Necrostatin-1 (Cayman, Ann Arbor, MI) were freshly dis-
solved in DMSO to make 40 mM stock solutions.
2.3. MTT assay
Cytotoxicity of compounds was evaluated with 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay. Cells were placed in 96-well plate at 1000 cells/well on
Day 1. After overnight attachment, SGI-110 was added to the
wells at sequential dilutions (10 nMe1 mM for most cell lines)
onDay 2. Due to the hydrolysis of the compound, SGI-110 treat-
ment was repeated every 24 h. After 72 h treatment (on Day 5),
SGI-110 containingmedia was carefully removed and fresh cell
culture media was added to the plate. For combination treat-
ment, oxaliplatinwas added onDay 5 after changing themedia,
and kept in culture for 72 h treatment. On Day 8, compound-
containing media was carefully removed and fresh cell culture
media was added to the plates. On Day 12, MTTwas added into
the media to a final concentration of 300 mg/mL. Cells were
incubated for 3 h at 37 C, and the insoluble formazan con-
verted by viable cells was dissolved in 150 mL of DMSO. Absor-
bance at 570 nm was read on a microplate reader (Molecular
Devices, Sunnyvale, CA), and inhibition of cell proliferation
was calculated using the following formula:
Inhibition of cell proliferation ð%Þ ¼ ð1ODtreatment =ODcontrolÞ
 100%
Synergistic effect of the combination treatment was evalu-
ated by computing combination index (CI) using the Chou-
Talalay method (Chou, 2006). CI values lower than 1 indicates
synergistic effect.
2.4. Colony formation assay
Cells were placed in a 96-well plate at 200 cells/well or in a 6-
well plate at 5000 cells/well on Day 1. Treatment schedules
were performed as described for the MTT assay. After treat-
ment, cells were kept in culture until colonies were observed
in control wells. Colonies were then fixed and stained with
0.05% crystal violet solution (2% formaldehyde, 40%methanol
in distilled water), washed with water to remove excess stain,
imaged with Odyssey Imaging Systems (LI-COR Biosciences,
Lincoln, NE), and quantified with Image J software.
2.5. Western blotting
Cells (4  105) were cultured in 60 mm tissue culture dishes
and treated with SGI-110 or oxaliplatin at designated concen-
trations. After treatment, cells were lysed with cell lysis buffer
at 4 C for 30 min and centrifuged (12,000 rpm, 10 min, 4 C).
Protein concentrations of supernatants were measured with
BCA assay (Thermo Fisher Scientific, Rockford, IL). 40 mg of
protein per sample was subjected to SDS-PAGE analysis. Pro-
teins were electro-transferred to methanol activated
immobilon-FL PVDF membranes (EMD Millipore, Billerica,
MA). Membranes were blocked with 5% skim milk in TBSTbuffer and incubated with primary antibodies (anti-E-Cad-
herin, anti-survivin, anti-PARP and anti-cleaved caspase 3
from Cell Signaling (Beverly, MA), anti-DNMT1 and anti-b-
tubulin from Santa Cruz Biotechnology (Santa Cruz, CA),
anti-ephrin-B2 and anti-PCNA from SigmaeAldrich (Saint
Louis, MO)) 1:1000 dilutions overnight at 4 C. Membranes
were then washed with TBST (10 min  3), incubated with
Dylight 800-conjugated secondary antibodies (Thermo Fisher
Scientific) 1:5000 dilutions in 5% milk for 1 h at room temper-
ature, and washed with TBST (10 min  2) and TBS (10 min).
Fluorescent signal was then scanned by Odyssey Imaging Sys-
tems (LI-COR Biosciences).
2.6. Bru-seq analysis for nascent RNA synthesis
Bru-seq analysis was performed as previously reported
(Paulsen et al., 2014). Briefly, 4 106 SNU-398 cells were placed
in 10 cm dishes on Day 1. On Day 2, cells were treatedwith PBS
or SGI-110 at 100 nM for 72 h with fresh drug addition every
24 h. Cells were changed to fresh media on Day 5 and treated
with DMSO or oxaliplatin at 3 mM for 4 h. Bromouridine, at a
final concentration of 2mM,was added into themedia to label
newly synthesized nascent RNA in the last 30 min of treat-
ment. Cells were then collected in TRIZOL and total RNA
was isolated. Bromouridine containing RNA population was
further isolated and sequenced. Sequencing reads were map-
ped to the HG19 reference genome. Pre-ranked gene lists were
generated for each treatment through ranking genes by fold
changes in gene synthesis levels compared to control, and
analyzed with GSEA (Broad Institute, MA) (Mootha et al.,
2003; Subramanian et al., 2005).
2.7. Xenograft study
SNU-398cells (2.0106) ina100mLsuspensionofRPMI1640were
injectedsubcutaneously intothedorsalflankof6-weekoldathy-
micnudemice (The Jackson Laboratory, BarHarbor,ME). Tumor
sizewasmonitored twice aweek by calipermeasurement using
the following equation: V ¼ d2D/2, where d represents width
and D represents length of the tumor. Mice were randomly
grouped (n ¼ 5 per group) when average tumor size reached
100 mm3. Treatment was given in 14-day cycles. On Day 1e5,
SGI-110 was administrated by subcutaneous injection in a
100 mL vehicle to SGI-110 single treatment and combination
groups. On Day 5 (4 h after SGI-110 administration) and Day 12,
oxaliplatin treatment was given by intraperitoneal injection in
100 mL saline to oxaliplatin single treatment and combination
group. Controlmice received vehicle only. Studywas concluded
when tumor size in the group reached 2000mm3. Unpaired Stu-
dent’s t-test was performed for data analysis and p < 0.05 was
considered significant.
2.8. Histochemical analysis
On necropsy, tumors, hearts, kidneys, livers, lungs, spleens
and pancreases were collected, fixed in 10% neutral buffered
formalin, embedded in paraffin, and sectioned. Sections
(5 mm) were stained with hematoxylin and eosin to facilitate
histologic examination. For Ki67 expression level, immuno-
histochemistry staining was performed on sections with
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were performed by the ULAM pathology core for animal
research at the University of Michigan. Representative images
were taken on an Olympus IX83 microscope with 20X
magnification.3. Results
3.1. SGI-110 inhibits HCC cell proliferation
To evaluate the potency of SGI-110 in HCC, we used six cell
lines with different genetic backgrounds as in vitro models.
Decitabine and SGI-110 showed similar cytotoxicity in Hep-
3B cells (Figure S2). After 72 h treatment, SGI-110 at 10 mM
inhibited cell proliferation by no more than 27% in the six
cell lines (Figure 1A, C). However, significant inhibition of
cell proliferation was observed when cells were treated with
SGI-110 for 72 h and placed in fresh cell culture media for 7
days (Day 12 of the experiment). Four of the HCC cell lines
Hep-3B, SNU-398, SNU-449 and Hep-G2 were more sensitive
to SGI-110, with IC50 values lower than 500 nM (Figure 1A).
SGI-110 also significantly inhibited colony formation in these
four cell lines at low mM (Figure 1B). The SNU-475 and SNU-
387 cells having doubling time of over 60 h (Park et al., 1995)
are more resistant to SGI-110 treatment. In long-term treat-
ment, SGI-110 showed an IC50 value of 54 mM in SNU-475 and
63 mM in SNU-387 in MTT and 10 mM in colony formation as-
says (Figure 1C, D). Since SGI-110 acts by incorporating into
DNA andmodifyingmethylation patterns during DNA synthe-
sis, the long doubling time of SNU-475 and SNU-387 might be
responsible for their lower sensitivity. SNU-475 cells are more
sensitive to SGI-110 treatment in colony formation assay than
inMTT assay supporting the notion that SGI-110’smechanism
of cytotoxicity is a combination of apoptosis, necrosis, and
other modes of cell death. As the direct target of SGI-110,
DNMT1 protein level is a robust marker for assessing treat-
ment efficacy. DNMT1 protein levels were depleted within
24 h of SGI-110 treatment (100 nM) in both SNU-398 and
Hep-G2 cells, and started to recover after SGI-110 removal,
confirming that SGI-110 directly targets DNMT1 for protein
degradation (Figure 1E). In conclusion, SGI-110 targets
DNMT1 and inhibits HCC cell proliferation in a long-term
treatment similar to other epigenetic-targeted drugs.
3.2. Pretreatment with SGI-110 sensitizes HCC cell lines
to oxaliplatin
Oxaliplatin was selected as a candidate for combination with
SGI-110 because in our studies it demonstrated superior syn-
ergistic effect when compared to several other FDA approved
drugs under similar conditions. Both oxaliplatin and the cur-
rent standard of care, sorafenib, produced higher IC50 values
in SNU-475 and SNU-387 cell lines than in SNU-398 and Hep-
G2 cells (Figure 2A). Initially, we observed that pretreatment
with SGI-110 sensitized HCC cells to oxaliplatin treatment.
The combination was hence further tested in three indepen-
dent schedules: 72 h SGI-110 pretreatment, where oxaliplatin
was given either with SGI-110 (schedule 1), immediately after
SGI-110 removal (schedule 2), or 72 h after SGI-110 removal(schedule 3) (Figure 2B). In colony formation assay, best syn-
ergy was observed with combination treatment using
schedule 2. Following this schedule, low-dose oxaliplatin sin-
gle treatment only inhibited colony formation by 15%, while
pretreatment with SGI-110 at 50 nM increased the inhibition
to 54%, and pretreatment with SGI-110 at 100 nM further
increased the inhibition to 94% (Figure 2C).
We further tested the combination effect of SGI-110 and
oxaliplatin in two SGI-110 sensitive cell lines (SNU-398, Hep-
G2) and two SGI-110 resistant cell lines (SNU-475, SNU-387) us-
ing MTT assay performed on Day 12 following schedule 2
(Figure 2B). Pretreatment with SGI-110 sensitized SNU-398,
Hep-G2 and SNU-475 cells to oxaliplatin treatment, achieving
over 50% inhibition of cancer cell proliferation with significant
synergism (Figure 2D, E), but was not optimal in the other less
sensitive cell line SNU-387. The synergistic effect was further
confirmedwith colony formation assay (Figure 2F), suggesting
the utility of combination of SGI-110 and oxaliplatin as an
effective therapy for HCC.
Pretreatment with the apoptosis inhibitor Z-VAD-fmk and/
orwith thenecroptosis inhibitor necrostatin-1partially rescued
SNU-398 cells from oxaliplatin induced cytotoxicity in the MTT
assay (Figure S3A). When cells were pre-treated with Z-VAD-
fmkand/ornecrostatin-1 and then treatedwithSGI-110 in com-
bination with oxaliplatin, only partial protection was observed
mainly when inhibitors were given 1 h before oxaliplatin
(Figure S3B, S3C). At higher doses of drugs no significant protec-
tion was observed with these inhibitors. The partial protection
by these two inhibitors demonstrates that apoptosis and nec-
roptosis are partly responsible for SGI-110 and oxaliplatin-
induced cytotoxicity and suggests that other death pathways
are also implicated. A cytostatic mechanism may also play a
role on the effect of combination treatment.
3.3. SGI-110 inhibits WNT3A and IGF/EGF signaling
To better understand the potential mechanism of SGI-110 and
oxaliplatin synergy, we performed Bru-seq to examine the
global changes in transcription in HCC cells. Pre-ranked gene
lists were analyzed with GSEA (Tables S1eS6). In SGI-110
treatment, we identified enrichment of gene sets that were
similarly upregulated by decitabine treatment in pancreatic
cancer cells (Figure S4) (Missiaglia et al., 2005). This finding
validates the similar transcriptional regulation by SGI-110
and decitabine, and it also suggests overlap of methylation-
regulated genes in HCC and pancreatic cancer.
Using the false discovery rate (FDR, q-value) of 0.25 as the
cut-off, oxaliplatin uniquely up-regulated a cluster of hyper-
methylated genes characterized in AML, but no other gene
setswere observed as positively associatedwith the treatment
(Figure 3A). In cells treated with SGI-110, the WNT3A gene set
was among themost highly upregulated sets by SGI-110 alone,
and it was the only significantly enriched gene set in the com-
bination treatment (Figure 3B). Heat map showing relative
synthesis levels indicates up-regulated expression of listed
genes by SGI-110 or its combination with oxaliplatin
(Figure 3C). WNT/b-catenin signaling is a major signature
pathway of liver cancer, where nearly half of HCC patients
exhibit activation of the pathway (Lachenmayer et al., 2012).
The enriched gene set represents genes down-regulated
Figure 1 e SGI-110 is cytotoxic to hepatocellular carcinoma cell lines. A) Dose-response curves for SGI-110 in 4 sensitive HCC cell lines. For
acute cytotoxicity (72 h), cells were treated with SGI-110 for 72 h (fresh drug added every 24 h) and subjected to MTT assay. For long-term
cytotoxicity (72 hD 7 d), cells were treated with SGI-110 for 72 h as above and changed to fresh cell culture media for seven days. MTT assay was
then performed to evaluate the number of live cells under each treatment condition. Inhibition of cell proliferation was calculated against PBS-
treated controls. Data points are shown as Mean ± SD from three independent experiments. B) Colony formation assay for SGI-110 in 4 sensitive
HCC cell lines. Cells were treated with SGI-110 for 72 h and left in culture in fresh media until colonies formed in PBS-treated controls. Colonies
were stained with crystal violet and imaged. C) Dose-response curves for SGI-110 in 2 resistant HCC cell lines from MTT assay as described in
panel A. D) Colony formation assay for SGI-110 in 2 resistant HCC cell lines as described in panel B. E) In SNU-398 cells and Hep-G2 cells,
DNMT1 levels were reduced by SGI-110 treatment in a time dependent manner. DNMT1 levels recovered after SGI-110 removal. Cells were
treated with SGI-110 at 100 nM for up to 72 h. Cell culture media containing SGI-110 were then removed and cells were changed into fresh
media. Samples were collected at indicated time points from 24 h to 168 h after SGI-110 removal.
M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 7 9 9e1 8 1 4 1803following WNT3A treatment (Labbe et al., 2007). Increased
synthesis of genes negatively regulated by WNT3A suggests
potential inhibition of WNT/b-catenin signaling by SGI-110
treatment. In support of this hypothesis, we found that the
expression levels of the endogenous b-catenin inhibitor, E-cadherin, were gradually upregulated after SGI-110 treatment.
In contrast, the b-catenin target gene, survivin, was down-
regulated consistent with the findings from GSEA (Figure 3D).
Among the gene sets negatively associated with treatments
(Figure 3E), GNF2_CCNB2 was selected as representative for
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downregulated by SGI-110 alone or with the combination treat-
ment (Figure 3F, H). Interestingly, the combination treatment
induced unique enrichment of the PACHER_TARGETS_O-
F_IGF1_ AND_IGF2_UP and MAGASHIMA_EGF_SIGNALING _UP
gene sets (Figure 3G), downregulating target genes from
Insulin-like growth factor (IGF) and epidermal growth factor
(EGF) signaling (Figure 3I), whose activation or overexpression
are often observed in HCC (Psyrri et al., 2012).
As revealed by GSEA, simultaneous inhibition of WNT/b-
catenin, IGF, and EGF signaling contributed to the synergistic
effect of the combination treatment.
3.4. SGI-110 treatment induces EFNB2 transcription
levels
Using Bru-seq to investigate the rates of transcription
genome-wide we observed that the transcription of the
EFNB2 gene was significantly upregulated in SNU-398 cells
by SGI-110 treatment (15.0 fold) andwhen combinedwith oxa-
liplatin (13.5 fold) (Figure 4A). When SNU-398 cells were
treated with SGI-110 for 72 h, protein levels of the EFNB2
gene product ephrin-B2 were increased dose-dependently,
where significant induction was observed at doses as low as
100 nM (Figure 4B). Upon treatment with SGI-110 (100 nM),
the expression of ephrin-B2 protein increased from 72 h post
treatment and achieved maximal induction at 96 h
(Figure 4C), consistent with the EFNB2 up-regulation after
72 h of SGI-110 treatment revealed by Bru-seq. Ephrin-B2 is a
ligand for tyrosine kinase receptor EPHB4 and EPHA4. In neu-
roblastoma, cells treatedwith decitabine re-expressed ephrin-
B2 and exhibited impaired proliferation (Tang et al., 2004). In
MethHC, a database of DNAmethylation and gene expression
in human cancers, EFNB2 is ranked 29th among the most
differentially methylated genes in the promoter region be-
tween tumor and normal samples. The increased average
methylation level was 0.2674 (in a 0e1 scale) in 204 hepatocel-
lular carcinoma samples from TCGA (Huang et al., 2015)
(Figure S5). This data suggests that EFNB2 can be a potential
biomarker for SGI-110 treatment in HCC.
However, in our efforts to further validate the role of EFNB2
in HCC, we found that SGI-110- induced ephrin-B2 expression
was only observed in SNU-398 among a panel of 12 cancer cellFigure 2 e SGI-110 pretreatment sensitizes SNU-398 cells to oxaliplatin tre
B) Schematic of three treatment schedules. SGI-110 was given in the first 72
time points after SGI-110 pretreatment. C) Representative images and quan
398 cells were coated on Day 0 and treated according to schedules 1, 2, 3 a
controls. Colonies were stained with crystal violet and imaged. Number of
Results are shown as Mean ± SD (n [ 3). P-values were calculated using S
(SNU-398, Hep-G2) and 2 less sensitive (SNU-475, SNU-387) HCC cell lin
followed by oxaliplatin for 72 h, and placed in fresh cell culture media. Con
100, 200, 400 nM in all cell lines, while oxaliplatin was given at 0.25e4 mM
MTT assay was performed on Day 12 to assess the number of live cells un
calculated against controls. Data points were shown as Mean ± SD from thr
oxaliplatin combination treatment at different concentrations (non-constan
synergistic effect of two compounds. F) Colony formation assay for SGI-110
SGI-110 for 72 h followed by oxaliplatin for 72 h, and kept in culture until
and imaged. Red lines indicate wells with significant synergistic effect fromlines that included 6 HCC cell lines (SNU-398, Hep-3B, SNU-
449, Hep-G2, SNU-475, SNU-387), 3 pancreatic cancer cell lines
(BxPC-3, Panc-1, MiaPaCa-2) and 3 other cancer cell lines
(HCT-116, LNCaP, U87), indicating that upregulation of
ephrin-B2 is cell line specific (Figure S6). Therefore, EFNB2 is
not a robust PD marker for efficacy of SGI-110 treatment, but
its importance in HCC needs to be further characterized.
3.5. Survivin is a new PD marker for SGI-110 and
oxaliplatin combination treatment
DNMT1 and survivin expression levels changed after SGI-110
treatment in a time dependent manner as discussed above.
To address their potential as PD markers, we evaluated the
expression levels of these proteins over different times of
SGI-110 and/or oxaliplatin treatments (Figure 5A). While oxa-
liplatin treatment did not affect DNMT1 protein levels in
SNU-398 cells (Figure 5B), SGI-110 treatment reduced DNMT1
levels in these cells. Following drug removal, DNMT1 protein
levels started to recover from SGI-110-induced depletion
within 72 h. Importantly, when oxaliplatin was given after
SGI-110 pretreatment, no recovery of DNMT1 protein levels
occurred. Survivin is a member of the inhibitor of apoptosis
family that directly inhibits apoptosis and promotes cell sur-
vival (Cheung et al., 2013). Survivin levels were downregulated
after long-term SGI-110 treatment as mentioned above. Inter-
estingly, survivin levels were not affected within 72 h of SGI-
110 or oxaliplatin treatment, but a significant decrease was
detectedwithin 48 h of the combination treatment, suggesting
a robust disruption of the survival signaling in these cells. We
further evaluated the levels of the apoptotic markers cleaved
PARP and caspase 3 after 72 h combination treatment. While
significant dose-dependent decrease in DNMT1 and survivin
levels were detected with the combination, only mild in-
creases of the two apoptotic markers were observed
(Figure S7), demonstrating that DNMT1 and survivin are
more robust biomarkers in SNU398 at this early time point.
To further validate these potential markers for the combi-
nation treatment, we performed the same experiment in
another sensitive cell line Hep-G2, and the least sensitive
cell lines SNU-475 and SNU-387. Similarly, the combination
treatment decreased the levels of survivin and blocked
DNMT1 protein recovery following SGI-110 removal in Hep-atment. A) IC50 values of sorafenib and oxaliplatin in HCC cell lines.
h (fresh drug added every 24 h), and oxaliplatin was added at different
titation of colony formation assay for the 3 treatment schedules. SNU-
s indicated. Cells were kept in culture until colonies were observed in
colonies at each treatment condition was quantified with Image J.
tudent’s t-test. D) Dose-response curves for oxaliplatin in 2 sensitive
es pretreated with SGI-110. Cells were treated with SGI-110 for 72 h
sidering different sensitivity of the cell lines, SGI-110 was given at 50,
in SNU-398 and Hep-G2, and 0.5e8 mM in SNU-475 and SNU-387.
der each treatment condition. Inhibition of cell proliferation was
ee independent experiments. E) Combination Index (CI) of SGI-110-
t ratio) was calculated using Chou-Talalay method. CI< 1 indicates
and oxaliplatin in SNU-398 and Hep-G2 cells. Cells were treated with
colonies were observed in PBS-treated control. Colonies were stained
the combination treatment.
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Figure 4 e EFNB2 expression is up-regulated by SGI-110 and its combination treatment with oxaliplatin. A) Synthesis of EFNB2 nascent RNA is
up-regulated by SGI-110 and its combination treatment with oxaliplatin in SNU-398 cells as identified by Bru-Seq. The gene map is from RefSeq
Genes (UCSC genome browser, http://genome.ucsc.edu/). B) Ephrin-B2 protein levels were up-regulated dose-dependently by SGI-110
treatment. C) Ephrin-B2 protein levels were up-regulated time-dependently by SGI-110 treatment, and the induced ephrin-B2 expression
remained up to 72 h after SGI-110 removal.
M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 7 9 9e1 8 1 4 1807G2 cells (Figure 5C). In order to achieve similar blockade of
DNMT1 recovery and decreased survivin levels in the
oxaliplatin-resistant SNU-475 cells, higher doses were
required when compared to the sensitive SNU-398 cells
(Figure 5D). In the other less sensitive cell line SNU-387, where
no significant synergismwas detected therewas no difference
in DNMT1 and survivin levels between single and combina-
tion treatments (Figure S8).
Considering their expression profiles across the 4 HCC cell
lines, the protein levels of DNMT1 and survivin reflect themo-
lecular responses of these cells to tested drugs, suggestingFigure 3 e Bru-Seq reveals inhibition of Wnt, IGF and EGF signaling by th
with SGI-110 at 100 nM for 72 h, followed by oxaliplatin at 3 mM for 4 h
collection, and subjected to RNA sequencing. 22,984 genes were analyzed an
The gene list were then pre-ranked by fold change of treatment over contro
positively associated with SGI-110, oxaliplatin or the combination treatment
considered true enrichment. B) Enrichment plots of LABBE_WNT3A_TA
lists from both SGI-110 and combination treatment. C) Heat map for rela
LABBE_WNT3A_TARGETS_DN gene set over-represented on the top o
D) In SNU-398 and Hep-G2 cells, E-Cadherin and survivin were modulat
SGI-110 at 100 nM for up to 72 h. Cell culture media containing SGI-110
Samples were collected at indicated time points from 24 h to 168 h after SG
oxaliplatin or the combination treatment. F) Enrichment plots of the GNF2
lists from both SGI-110 and combination treatment. Several computationa
manner, and GNF2_CCNB2 was selected as a representative. G) Enrichmen
ranked gene list from the combination treatment only. H) Heat map for rela
and GNF2_CDC20 gene sets, which were over-represented on the bottom o
I) Heat maps for relative transcription level of genes in the IGF/EGF gene
combination treatment only.that they could be used as novel PD markers for the effective-
ness of the combination treatment.
3.6. SGI-110 as single agent and in combination with
oxaliplatin delays tumor growth without systemic toxicity
To investigate the in vivo antitumor efficacy of SGI-110 alone
and in combination with oxaliplatin, xenograft studies were
performed in athymic nude mice. Subcutaneous human HCC
xenografts from SNU-398 cells were established on the dorsal
flank of the immunodeficient mice, and treated with SGI-110,e combination of SGI-110 and oxaliplatin. SNU-398 cells were treated
. Nascent RNA was labeled by bromouridine 30 min before sample
d filtered by gene size (>300 bp) and synthesis level (RPKM> 0.5).
l and subjected to Gene Set Enrichment Analysis. A) Top 5 gene sets
. Gene sets with false discovery rate (FDR) q-value lower than 0.25 are
RGETS_DN gene set over-represented on the top of pre-ranked gene
tive transcription level of genes in the
f pre-ranked gene lists from both drugs and combination treatment.
ed by SGI-110 in a time dependent manner. Cells were treated with
were then removed and cells were left to recover in fresh cell media.
I-110 removal. E) Top 5 gene sets negatively associated with SGI-110,
_CCNB2 gene set over-represented on the bottom of pre-ranked gene
l gene sets for cancer gene neighborhood were enriched in the same
t plots of IGF/EGF gene sets over-represented on the bottom of pre-
tive transcription level of genes in the additive list of GNF2_CCNB2
f pre-ranked gene lists from both SGI-110 and combination treatment.
sets over-represented on the bottom of pre-ranked gene list from the
Figure 5 e Oxaliplatin treatment down-regulates DNMT1 and survivin levels in SGI-110 pre-treated cells. A) Schematic for SGI-110 and
oxaliplatin treatment. Cells were treated with SGI-110 for 72 h, changed to fresh media and treated with oxaliplatin for up to 72 h. Samples were
collected every 24 h after SGI-110 treatment to study the time course effects of SGI-110 and oxaliplatin treatments. Control, oxaliplatin, SGI-110
and combination treated cell lysates were blotted for DNMT1 and survivin. Representative results are shown for B) SNU-398, C) Hep-G2 and D)
SNU-475 cells.
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group reached 2000 mm3 (Figure 6A). Treatments were given
in 14-day cycles, where SGI-110 (2 mg/kg) was given daily on
Day 1e5, and oxaliplatin (5 mg/kg) was given on Day 5 (4 h af-
ter SGI-110 administration) and Day 12. Weekly oxaliplatin
treatment was selected based on its efficacy and safety profile
reported in previous studies (Selvakumaran et al., 2013; Gauret al., 2014; Zeng et al., 2014). In our experience, oxaliplatin
shows significant toxicity when used at doses higher than
10mg/kg or using repetitive dosing. In an ongoing phase II trial
(NCT01752933), SGI-110 was given on five consecutive days
followed by a 23-day recovery, rather than a more frequent
schedule. Considering the in vivo half-life of SGI-110 of 4 h
(Yoo et al., 2007; Tellez et al., 2014), the first oxaliplatin
M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 7 9 9e1 8 1 4 1809treatment in the 14-day cycle was given 4 h after the last daily
SGI-110 treatment on Day 5, matching the optimal oxaliplatin
treatment schedule established in Figure 2. Although oxalipla-
tin (5 mg/kg) did not show efficacy, SGI-110 (2 mg/kg) treat-
ment significantly suppressed growth of tumors after 15
days of treatment. Combination with oxaliplatin further
delayed tumor growth, where significant difference in tumor
sizes was achieved as early as day 8. On day 19, when average
tumor sizes in control and oxaliplatin treatment groups
passed the experiment endpoint of 2000 mm3, the average tu-
mor size was 1010  247 mm3 ( p¼ 0.0039) for SGI-110 treat-
ment alone, and only 391  100 mm3 ( p¼ 0.0001) for
combination with oxaliplatin. SGI-110 treatment was able to
delay endpoint from day 19 to day 26, and combination treat-
ment further delayed the endpoint to day 31 (Figure 6B), indi-
cating substantial survival benefits from the treatments.
Mice were sacrificed and samples were collected when the
tumor sizes reached 2000 mm3 in all groups. The tumor sam-
ples from control and oxaliplatin treatment groups were
collected on Day 19, while the samples from the SGI-110 and
combination groups were collected on Day 26 and Day 31,
respectively. Despite reaching the samemaximum tumor vol-
ume of 2000mm3, the tumors receiving SGI-110 treatment as a
single agent or in combination with oxaliplatin showed a sig-
nificant decrease in Ki67 levels, suggesting reduction in cell
proliferation (Figure 6C).
Evaluation of the potential PDmarkers in tumor tissues un-
veiled that DNMT1 levels were significantly downregulated in
the combination group and mildly decreased with SGI-110
treatment, whereas no significant changes were detected
with vehicle or oxaliplatin treatment. Similar to our results
in in vitro experiments, survivin protein levels were markedly
decreased with the combination (Figure 6D). These findings
further validate these two PD markers to measure efficacy of
the combination treatment, suggesting their potential use in
future clinical studies.
No systemic symptoms of toxicity such as weakness,
weight loss or lethargy were observed in any treatment group
(Figure 6E). H&E stained organ sections of liver, kidney, heart,
lung, spleen and pancreas did not reveal major histopatholog-
ical changes, further confirming the safety of the treatments
(Figure 6F).4. Discussion
Accumulating pre-clinical data has suggested epigenetic ther-
apy as an appealing strategy to target HCC. However, when
decitabine was tested in several clinical trials in solid tumors
such as colon and lung cancers (Graham et al., 2009; Fan et al.,
2014), no efficacy was observed as single agent. Compelling
preclinical data has prompted phase II trials of combination
treatmentwith decitabine and carboplatin in relapsed ovarian
cancer patients. When decitabine was given at 90 mg/m2,
combination-induced neutropenia became a major issue
that lead to closure of the study (Glasspool et al., 2014). How-
ever, low dose (10 mg/m2) decitabine treatment successfully
re-sensitized heavily pretreated ovarian cancer to carboplatin,
achieving 35% objective response rate and progression-free
survival of 10.2 months among 17 patients (Matei et al.,2012), suggesting great potential for low dose hypomethylat-
ing agent combination treatment in solid tumors. The devel-
opment of the second generation hypomethylating agent,
SGI-110, represents an improvement over decitabine. SGI-
110 treatment provides a longer exposure window than deci-
tabine with lower maximal concentrations. These features
may make it more amenable to combine with anticancer
agents. Our preclinical studies with SGI-110 in the six HCC
cell lines and the xenograft model demonstrated significant
antitumor activity of SGI-110 and synergism when used in
combination with oxaliplatin. These preclinical data provide
a strong rationale for the further testing of SGI-110 in clinical
trials.
As a demethylating agent, SGI-110 is expected to change
cellular DNA methylation profiles to restore a more normal
transcriptome leading to antitumor activity. To elucidate the
potential mechanisms of SGI-110 as single agent and in com-
bination with oxaliplatin, we have employed Bru-seq, which
captures gene synthesis without RNA post-transcription pro-
cessing, allowing direct assessment on gene transcription sta-
tus after epigenetic modulation. Instead of studying only the
select genes or targets predicted by previous studies, Bru-seq
provides an un-biased method to explore changes in nascent
RNA synthesis for the whole genome. Gene sets enrichment
analysis (GSEA) of the Bru-seq data revealed inhibition of
WNT/b-catenin signaling with SGI-110 treatment. It is note-
worthy that synergistic effects of SGI-110 and oxaliplatin
were only observed in cell lines with mutation induced
WNT/b-catenin pathway activity (Hep-G2 and SNU-398 both
possess mutation in CTNNB1, and SNU-475 has deletion in
AXIN1 (Satoh et al., 2000; Yuzugullu et al., 2009)), but not in
SNU-387 that has no such genetic aberrations. Suggested by
these data, theWNT/b-catenin signalingmight be amajor tar-
geted pathway as well as a potential patient selection marker
for SGI-110 treatment. Another interesting finding is the
down-regulation of cancer gene neighborhood sets by SGI-
110. Defined by correlated expression with certain cancer-
associated genes in the human tissue compendia, such
computational gene sets represent cancer-oriented features
of the transcriptome. It is still unclear whether it is the direct
effect from SGI-110 or secondary effect from a primary modu-
lation of up-stream targets; however, this significant enrich-
ment of cancer-associated gene sets at the bottom of our
pre-ranked gene list implies an overall suppression of
cancer-specific features by SGI-110 treatment.
In the combination treatment, the EGF and IGF signaling
pathways were uniquely inhibited as revealed by Bru-seq,
implying a potential mechanism for the synergistic effect of
SGI-110 and oxaliplatin. Considering the substantial molecular
changes in liver cancer, targeting multiple signature pathways
with one treatment regimen is a plausible strategy. In HCC,
overexpression of EGFR proteins and amplification of the EGFR
gene were confirmed with Immunohistochemistry and FISH
studies by Buckley et al. (Buckley et al., 2008). However, single
treatment targeting EGFR with gefitinib (O’Dwyer et al., 2006),
cetuximab (Zhu et al., 2007) or lapatinib (Bekaii-Saab et al.,
2009) has not shown efficacy in Phase II studies. In a recent
phase III clinical trial of erlotinib in combinationwith sorafenib
that evaluated 720 advanced HCC patients, no significant
improvement in survival was observed with erlotinib plus
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survival of 9.5 vs. 8.5months) (Zhu et al., 2015). This study high-
lights the refractory nature ofHCC and suggests that EGFR inhi-
bition is not an effective treatment for HCC. For the Insulin-like
growth factor (IGF) axis, overexpression or aberrant activity of
the pathway has been reported in HCC (Yang et al., 2003;
Hopfner et al., 2006; Desbois-Mouthon et al., 2009). Although
preclinical studies suggested growth inhibitory effects of the
IGF-1R monoclonal antibody cixutumumab (Tovar et al., 2010),
a Phase II study with cixutumumab monotherapy did not
show clinically meaningful efficacy in unselected HCC patient
populations (Abou-Alfa et al., 2014). Interestingly, treatment
with the IGF-1R antibody AVE1642 caused activation of HER3
in an EGFR-dependent manner counteracting its growth inhib-
itory effects. When AVE1642 was combined with the EGFR in-
hibitor gefitinib, significant reduction of HCC cell viability was
achieved (Desbois-Mouthon et al., 2009). On the other hand,
activation and nuclear translocation of IGF-1R was observed
in an induced gefitinib-resistant HCC cell line (Bodzin et al.,
2012). These studies highlight the compensatory nature of the
two signature pathways, suggesting that simultaneous inhibi-
tion of EGFR and IGF-1R could be effective in HCC treatments.
In our studies, the combination of SGI-110 and oxaliplatin sup-
pressedactivity ofbothpathways inaddition to the inhibitionof
the expression of WNT/b-catenin signaling genes. Simulta-
neous suppression of these three major signature pathways
supports the great potential for the combination of SGI-110
and oxaliplatin in treating HCC.
Another important goal of this preclinical study was to
establish potential PD markers for future clinical evaluations.
EFNB2 was identified by Bru-seq to be increased by SGI-110
treatment in the HCC cell line SNU-398. Ephrin-B2/EPHB4
signaling is known to suppress tumor growth in neuroblas-
toma (Tang et al., 2004), breast (Noren et al., 2006) and colon
cancers (Liu et al., 2002). This is the first study to report upre-
gulation of ephrin-B2 levels by hypomethylating agents in
liver cancer. We observed significant induction of ephrin-B2
expression in SNU-398 cells by SGI-110 as single agent and
in combination treatment with oxaliplatin. Also hypermethy-
lation in EFNB2 promoter regions in HCC patient samples was
observed in TCGA studies (Figure S5), suggesting the potential
for SGI-110 mediated regulation of EFNB2 gene transcription
in HCC. However, studies with additional HCC cell lines did
not support ephrin-B2 induction as a PD marker for efficacy
of the SGI-110 treatment.
In addition to the decitabine targets DNMT1, survivin was
also identified as a PD marker for the efficacy of the SGI-110Figure 6 e Single agent SGI-110 and its combination treatment with oxalip
A) Treatment schedule. Mice with SNU-398 tumors were randomized into
weekly), SGI-110 (2 mg/kg from day 1 to day 5 in a 2-week cycle) or comb
2000 mm3. B) Tumor sizes were significantly reduced in mice treated with
combination treatment. Statistical significance was calculated using Studen
****p< 0.0001. C) Ki67 immunohistochemistry staining in tumor sections.
number of cells in the field (n[ 6, 3 fields of view from 2 tumors per group
using Student’s t-test. D) Lysates from 3 tumors per treatment group were
treatment with oxaliplatin did not exert systemic toxicity in vivo. Animal wei
bars indicate Mean ± SEM. F) Representative micrographs of hematoxylin
Olympus IX83 inverted microscope at 20X magnification. In histopatholog
organs after SGI-110 or combination treatment.and oxaliplatin combination treatment. As a member of the
inhibitor of apoptosis protein (IAP), survivin is overexpressed
in most cancers. Inhibition of survivin promotes cell death
in cancer cells (Kelly et al., 2011). In liver cancer, survivin
was identified as a target gene of Wnt/b-catenin pathway
(Gedaly et al., 2014). In our studies, combination treatment
in SNU-398, Hep-G2 and SNU-475 cells decreased survivin
levels rapidly where neither SGI-110 nor oxaliplatin single
treatment affected survivin levels. Downregulation of survivin
levels was also observed following the combination treatment
in SNU-398 tumors. Interestingly, no change in survivin levels
was observed following the combination treatment in SNU-
387 cells, in which the combination did not show synergistic
effect. We conclude from our data that the expression levels
of survivin correlated well with the cytotoxicity of the combi-
nation treatments, suggesting that survivin may be an impor-
tant effector of the synergism. These results imply that
survivin can be used as a PD marker in response to SGI-110
and oxaliplatin treatment.
Since toxicity is an important factor for combination treat-
ments in vivo as compared with in vitro studies, we have cho-
sen to give weekly oxaliplatin treatment and precede the first
oxaliplatin treatment with SGI-110 in a 14-day cycle. Oxalipla-
tin weekly treatment has been routinely used for in vivo
studies, while it is mostly given once every two weeks in the
clinic due to its toxicity. To best evaluate clinical relevant
schedules and doses, as well as to avoid potential toxicity
introduced by the combination, we chose to give oxaliplatin
at 5 mg/kg once a week. Decitabine or SGI-110 can be toxic
as long-term repeated treatment. Based on previous studies,
QD5 treatment or bi-weekly treatment is used to achieve ther-
apeutic effect without systemic toxicity. In SCID mice model,
SGI-110 given as daily treatment for 5 consecutive days at
3 mg/kg showed consistent and robust hypomethylation and
induction of Cancer Testis Antigen (CTA) genes in leukemia
as well as ovarian cancer xenografts without significant
toxicity (Srivastava et al., 2014, 2015), suggesting good balance
between efficacy and toxicity at this treatment schedule. In
the ongoing phase II clinical trial of SGI-110 for the treatment
of advanced HCC (NCT01752933), SGI-110 is given daily on
Days 1e5 every 28 days. In our studies, SGI-110 at 2 mg/kg
was administered on Days 1e5 in a 14-day cycle.
SGI-110 treatment delayed tumor growth endpoint from 19
to 26 days supporting a benefit in survival. More importantly,
the combination with oxaliplatin further delayed tumor
growth endpoint to 31 days, demonstrating synergism. The
combination treatment was well tolerated with no apparentlatin inhibit tumor growth in SNU-398 liver cancer xenograft model.
4 treatment groups (n[ 5) and received vehicle, oxaliplatin (5 mg/kg
ination treatment. Mice were sacrificed when tumor size reached
SGI-110, and further delayed in mice with SGI-110 and oxaliplatin
t’s t-test. Error bars indicate Mean ± SEM. and *p< 0.05,
Ki67 index was calculated as percentage of Ki67 positive cells in total
). Graphical data is presented as Mean ± SD. P-values were calculated
blotted for DNMT1 and survivin. E) SGI-110 and its combination
ghts did not change significantly during the course of treatment. Error
and eosin (H&E)-stained organ sections. Images were taken with an
y study, no significant morphological changes were detected in major
MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 7 9 9e1 8 1 41812weight loss or gross toxicity in major organs. Based on our
in vitro data and the safety of combination treatment, we
believe that higher doses of oxaliplatin or SGI-110will improve
the therapeutic effect for the combination treatment. This can
be further investigated in future preclinical or clinical studies.
In this preclinical study, we have shown significant anti-
tumor effect of SGI-110 alone or in combination with oxalipla-
tin in HCC models. Application of Bru-seq led to the
identification of Wnt/b-catenin, EGFR and IGFR signaling as
key pathways inhibited by the combination treatment. Such
simultaneous inhibition of three liver cancer signature path-
ways by the combination treatment supports the use of a
DNA demethylating agent in combination with a cytotoxic
agent as an effective therapy for HCC.We expect that the com-
bination of SGI-110 and oxaliplatin at low doses will delay dis-
ease progression and prolong overall survival without
significant toxicity. Our findings provide strong rationale for
a Phase I/II clinical trial with SGI-110 and oxaliplatin in HCC
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